- Immutep Ltd Annual Shareholders Meeting TranscriptOct 23, 2023
- Immutep Ltd ShareCafe Hidden Gems Webinar TranscriptJun 26, 2023
- Immutep Ltd at Jefferies Healthcare Conference TranscriptJun 08, 2023
- KOL Event hosted by Ladenburg Thalmann & Co, Inc. TranscriptMay 09, 2023
- Immutep Ltd at Jefferies London Healthcare Conference TranscriptNov 17, 2022
- Immutep Ltd at Ladenburg Thalmann Healthcare Conference TranscriptSep 29, 2022
- Immutep Ltd Annual Shareholders Meeting TranscriptNov 25, 2021
- Immutep Ltd at ASX Small & Mid-Cap Virtual Conference TranscriptSep 08, 2020
- Immutep CEO presentation BIO Asia-Taiwan TranscriptJul 09, 2020
- Immutep TACTI-002 and INSIGHT Global Webcast Slides TranscriptJun 02, 2020
- Immutep Ltd at NWR Communications Virtual Health Conference TranscriptMay 04, 2020
- Immutep Ltd Call For Topline Data From The Phase IIb AIPAC Study In HER2-negative/HR+ Metastatic Breast Cancer TranscriptMar 25, 2020
- Immutep Ltd TACTI-002 Clinical Results & Update Global Webcast TranscriptFeb 25, 2020
- Immutep Ltd Eftilagimod Alpha Clinical Development Update And New Data From Ongoing Melanoma Study TranscriptApr 02, 2019
- Immutep Ltd IMP761 Preclinical Results In Global Webcast TranscriptMar 25, 2019
Immutep Ltd Call For Topline Data From The Phase IIb AIPAC Study In HER2-negative/HR+ Metastatic Breast Cancer Transcript
Greetings, and welcome to Immutep's call for top line data from the Phase IIb AIPAC study and HER2-negative HR metastatic breast cancer conference call. (Operator Instructions) Please note, this conference is being recorded.
I will now turn the conference over to your host, Tim McCarthy, Managing Director of LifeSci Advisors. Please go ahead.
(technical difficulty)
on the company's AIPAC study of its lead product candidate, eftilagimod alpha. I will be your moderator today. And at the end of the presentation, I will ask questions we received via e-mail prior to this call.
I would now like to hand over the call to Marc Voigt, Immutep's CEO, to start the presentation. Marc?
Yes. Thank you very much, Tim. And thank you all, and welcome, everyone. We are pleased to have you to join us on the call today. Especially also given the COVID
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)